Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Abstract Background Alzheimer’s disease is a neurodegenerative disorder, and Aβ aggregation is considered to be the central process implicated in its pathogenesis. Current treatments are faced by challenges such as serious side effects and reduced drug bioavailability. In this study, we developed a...

Full description

Bibliographic Details
Main Authors: Yi-Wen Lin, Chih-Hsiang Fang, Ya-Jyun Liang, Ching-Yun Yang, Wei-Ting Kuo, Feng-Huei Lin
Format: Article
Language:English
Published: American Association for the Advancement of Science (AAAS) 2023-10-01
Series:Biomaterials Research
Subjects:
Alzheimer’s disease
Amyloid beta
Clenbuterol
Hydroxyapatite
Controlled release
Online Access:https://doi.org/10.1186/s40824-023-00432-4

Similar Items

Similar Items